BAM
ALDX icon

Belpointe Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Belpointe Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50
Closed -$497 – 691
2023
Q1 		$497 Hold
50
– – ﹤0.01% 3591
2022
Q4 		$348 Buy
+50
New +$286 ﹤0.01% 3582

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Belpointe Asset Management's ALDX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 50 shares — an estimated $497 sold.

Belpointe Asset Management first reported a position in ALDX in Q4 2022 and held it in 2 quarters. The position peaked at $497 in Q1 2023. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 50 Aldeyra Therapeutics shares in Q2 2023, an estimated $497.
  • Belpointe Asset Management first reported a position in Aldeyra Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Aldeyra Therapeutics position peaked at $497 in Q1 2023.
  • 119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.